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RESEARCH ARTICLE Open Access
Intestinal Epithelial Serum Amyloid A Modulates
Bacterial Growth In Vitro and Pro-Inflammatory
Responses in Mouse Experimental Colitis
Erik RM Eckhardt1,2*†, Jassir Witta2†, Jian Zhong2, Razvan Arsenescu2, Violeta Arsenescu1,2, Yu Wang1,
Sarbani Ghoshal2, Marcielle C de Beer2, Frederick C de Beer2, Willem JS de Villiers2
Abstract
Background: Serum Amyloid A (SAA) is a major acute phase protein of unknown function. SAA is mostly
expressed in the liver, but also in other tissues including the intestinal epithelium. SAA reportedly has anti-bacterial
effects, and because inflammatory bowel diseases (IBD) result from a breakdown in homeostatic interactions
between intestinal epithelia and bacteria, we hypothesized that SAA is protective during experimental colitis.
Methods: Intestinal SAA expression was measured in mouse and human samples. Dextran sodium sulfate (DSS)
colitis was induced in SAA 1/2 double knockout (DKO) mice and in wildtype controls. Anti-bacterial effects of
SAA1/2 were tested in intestinal epithelial cell lines transduced with adenoviral vectors encoding the CE/J SAA
isoform or control vectors prior to exposure to live Escherichia coli.
Results: Significant levels of SAA1/SAA2 RNA and SAA protein were detected by in situ hybridization and
immunohistochemistry in mouse colonic epithelium. SAA3 expression was weaker, but similarly distributed. SAA1/2
RNA was present in the ileum and colon of conventional mice and in the colon of germfree mice. Expression of
SAA3 was strongly regulated by bacterial lipopolysaccharides in cultured epithelial cell lines, whereas SAA1/2
expression was constitutive and not LPS inducible. Overexpression of SAA1/2 in cultured epithelial cell lines
reduced the viability of co-cultured E. coli. This might partially explain the observed increase in susceptibility of
DKO mice to DSS colitis. SAA1/2 expression was increased in colon samples obtained from Crohn’s Disease
patients compared to controls.
Conclusions: Intestinal epithelial SAA displays bactericidal properties in vitro and could play a protective role in
experimental mouse colitis. Altered expression of SAA in intestinal biopsies from Crohn’s Disease patients suggests
that SAA is involved in the disease process.
Background
Serum Amyloid A (SAA) is an acute-phase protein, of
which the expression can increase orders of magnitude
during infections and stress responses. However, the
exact function of SAA is not clear. SAA is evolutionarily
strongly conserved, and has been detected in all verte-
brates studied to date. Four SAA isoforms have been
described in humans and mice [1]. SAA1 and SAA2
represent the main acute-phase isoforms, and are mainly
expressed in the liver. SAA3, which is induced during
acute and chronic inflammatory responses, is predomi-
nantly expressed by macrophages [2]. A fourth isoform,
SAA4, is constitutively expressed [3].
SAA structurally resembles an apolipoprotein, and is
mainly transported in association with lipoprotein parti-
cles, particularly high-density lipoprotein (HDL) [4,5].
During an acute phase response, SAA becomes the
main apolipoprotein on HDL, and the displaced Apo-AI
[1,5] then becomes available to extract cellular free cho-
lesterol upon interacting with cell-surface ABCA1 [6].
For this reason, and because SAA itself may also extract
cholesterol from cells [7,8], it is thought that SAA plays
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a role in cholesterol metabolism and atherosclerosis
[9,10]. Whether SAA is pro- or anti-atherogenic is not
yet clear, however, since putative beneficial effects on
cholesterol metabolism may be mitigated by effects on
inflammation, a know risk factor for atherosclerosis [11].
SAA may affect inflammatory responses by activating
its putative receptor on neutrophils (FPRL1), leading to
increased production of IL-8 [12]. SAA is also thought
to be able to activate TLR2- and TLR4- dependent sig-
naling [13,14]. Recent reports suggest that SAA may
also play a role in host defense, notably in the clearance
of Gram-negative bacteria. Shah et al. demonstrated that
SAA binds to outer membrane protein A of Escherichia
coli, which facilitated bacterial clearance by phagocytes
[15]. Such a bactericidal effect of SAA is intriguing in
light of the reported expression of SAA in intestinal
epithelia of rodents [16] and humans [17], since these
cells are exposed to many gram-negative bacteria [18].
The intestinal epithelium employs several mechanisms
to minimize infiltration and translocation of bacteria,
including a mucous layer [19], secretion of immunoglo-
bulin A [20], and the release of an array of anti-
microbial proteins and peptides, such as defensins/crypt-
dins, phospholipases, lysozyme, and Reg III-gamma
[19,21-24]. Failure to properly induce and maintain
these defense mechanisms, e.g. through defects in sen-
sing mechanisms for bacterial products, may increase
the risk for inflammatory bowel diseases (IBD) [25,26].
It is therefore important to characterize the entire spec-
trum of anti-microbial mechanisms deployed by intest-
inal epithelial cells.
We hypothesized that SAA would be protective in
experimental colitis, by aiding in the killing of Gram-
negative bacteria. To test this hypothesis, we generated
double knockout (DKO) mice in which the genes encod-
ing the two major acute phase isoforms, SAA1 and
SAA2, were inactivated. These mice were challenged
with DSS in their drinking water to induce acute colitis.
We also tested whether over-expression of SAA in cul-
tured enterocytes would reduce the viability of co-cul-
tured E. coli. In this report, we confirm epithelial
expression of SAA in wildtype mice and present evi-
dence that DKO mice are more susceptible to DSS-coli-
tis. Intestinal epithelial SAA strongly reduced the
viability of co-cultured E. coli in vitro. Acute phase SAA
expression was increased in intestinal biopsies of
Crohn’s Disease patients. Thus, SAA may represent a
novel factor in intestinal-epithelial immune homeostasis.
Methods
Animals
C57BL/6J mice were purchased from The Jackson
Laboratory (Bar Harbor, Maine, USA) for histological
examination of SAA expression. The generation of
SAA1/SAA2 double knockout mice is described else-
where in the Methods section. All animals were main-
tained on a 12-hour light/12-hour dark cycle under
specific pathogen-free conditions. The mice had free
access to standard rodent diet and water. Frozen intest-
inal tissue samples from germfree mice (Swiss Webster)
were ordered from Taconic. All animals were handled
in strict accordance with good animal practice as
defined by the relevant national and local animal welfare
bodies, and all animal work was approved by the Institu-
tional Animal Care and Use Committee of the Univer-
sity of Kentucky.
In situ hybridization
C57Bl/6 mice were euthanatized by CO2 asphyxiation.
Colons and small intestines were frozen in “Optimum
Cutting Temperature” (OCT) mounting medium on dry
ice, sectioned (16 μm thickness) with a cryostat at -16°C,
mounted on Superfrost/Plus slides (Fisher Scientific, Ver-
non Hills, IL), dried at 37°C, and processed for in situ
hybridization. Briefly, sections were washed with phos-
phate-buffered saline, quickly dehydrated in a series of
solutions with increasing ethanol content, and de-lipi-
dated in chloroform. Sections were hybridized overnight
in a humid chamber at 55°C using radiolabeled [35S]
probes (106 dpm/60 μl) in hybridization buffer (20
mMTris-HCl, pH 7.4, 1 mM EDTA, 300 mM NaCl, 50%
formamide, 10% dextran sulfate, 1 × Denhardt’s solution).
The slides were washed four times for 5 min each in 4×
standard saline citrate (SSC) containing 1 mM DTT. To
remove single-stranded RNA, sections were washed for
30 min at 37°C in a solution containing RNase A (20 μg/
ml). Slides were then washed for 5 min each at room
temperature in solutions containing decreasing amounts
of SSC (2×SSC, 1×SSC and 0.5×SSC; all with 1 mM
DTT), and then washed two times for 30 min at 65°C in
0.5×SSC/1 mM DTT. Sections were cooled to room tem-
perature and dehydrated in ethanol. Slides were then
dipped in undiluted Kodak NTB2 emulsion, exposed for
five weeks, developed, and then counterstained with
Giemsa.
Probe preparation
Riboprobes were prepared using [35S]-UTP and the
Maxiscript kit (Ambion, Austin, TX) according to the
manufacturer’s directions. The following templates were
used: Mouse SAA1 and SAA2, a fragment of cDNA
(GenBank Accession No. M11130) corresponding to
nucleotides 388-606 of the coding sequence. Mouse
SAA3, a fragment of cDNA (GenBank Accession No.
BC055885) corresponding to nucleotides 376-529 of the
coding sequence. [35S]-UTP labeled antisense and sense
probes were generated by T7 and T3 RNA polymerase
using linearized templates, respectively.
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Immunostaining and immunoblotting
Colon sections were fixed in 4% paraformaldehyde in
phosphate-buffered saline (PBS), washed in PBS, and
incubated in 1% bovine serum containing 0.6% Triton
X-100. Slides were incubated overnight with rabbit poly-
clonal antiserum against purified mouse SAA (generated
by Lablogix corporation), washed, and incubated with
fluorescein-isothiocyanate (FITC)-conjugated secondary
antibody (Jackson ImmunoResearch Laboratories, West
Grove, PA). Slides were washed with PBS, mounted in
anti-fade mounting medium (Vectashield, Vector
Laboratories, Burlingame, CA), and viewed with an epi-
fluorescence microscope (model BX50; Olympus Opti-
cal, Melville, NY) equipped with a cooled charge-
coupled device camera. Images were digitally acquired
using MagnaFire 2.1A software, and recompiled in
Adobe Photoshop, version 5.0. Sections stained with
secondary antibody alone did not show reactivity (data
not shown). Extracts of feces isolated from the ascend-
ing colon were prepared by adding radio-immunopreci-
pitation assay buffer (RIPA) to freeze-dried pellets.
Boiled and reduced fecal extracts and samples from con-
ditioned medium of adenovirus-treated epithelial cells
were subjected to SDS-polyacrylamide gel electrophor-
esis, transferred to PVDF membranes, incubated with
rabbit anti-SAA, and developed after incubation with
horseradish peroxidase conjugated goat-anti rabbit IgG.
Generation of SAA1 and SAA2 double knockout (DKO)
mice
Targeted deletion of both mouse acute phase SAA genes
Saa1 and Saa2 was performed by InGenious Targeting
Laboratory Inc. (Stony Brook, NY) using embryonic
stem cells derived from C57BL/6 × 129 SVEV mice.
The targeting vector contained a neo cassette that
replaced ~ 10.1 kb of the Saa1 and Saa2 genes, which
included exon 2 of both oppositely orientated genes.
The knockout mice are currently being backcrossed into
C57Bl/6 mice, and the same is done with a parallel
cohort of C57BL/6 × 129 SVEV mice. Mice from similar
generations of both groups of mice, i.e. DKO mice and
C57Bl/6 × 129 SVEV mice as control, were used for
DSS colitis experiments.
Induction of colitis
Colitis was induced in 10 weeks old male DKO mice or
controls, by adding 3% dextran-sodium sulfate (DSS;
molecular weight 40,000 Da; ICN Biomedicals, Aurora,
Ohio, USA) to the drinking water, for 7 days. Controls
received untreated water. The mice were examined on
day 9 for weight loss, colon length, and blood hematocrit
(HCT). Paraffin sections of the colons were microscopi-
cally analyzed and scored with a histological disease
index, as described previously [27]. All procedures using
animals had been reviewed and approved by the Institu-
tional Animal Care and Use Committee of the University
of Kentucky, and were performed according to the cri-
teria outlined by the NIH.
Real-time PCR of mouse colon samples
RNA from colon samples from mice treated with DSS
were reverse transcribed into cDNA, which was then
analyzed for the expression of TNFalpha and osteopon-
tin (a pro-inflammatory cytokine which is associated
with DSS colitis [28]) relative to GAPDH by real-time
PCR using the following primer pairs: GGC-AGG-TCT-
ACT-TTG-GAG-TCA-TTG/GTT-AGA-ACA-CAG-
ACT-GG (TNFalpha), AGC-AAG-AAA-CTC-TTC-
CAA-GCA-A/GTG-AGA-TTC-GTC-AGA-TTC-ATC-
CG (osteopontin), CCA-GGT-TGT-CTC-CTG-CGA-
CTT/CCT-GTT-GCT-GTA-GCC-GTA-TTC-A
(GAPDH).
Cell culture studies
CMT93 (a murine rectal epithelial cell line) and HT29 (a
human colonic adeno-carcinoma line) intestinal epithelial
cells were purchased from American Type Culture Col-
lection (ATCC; Manassas, VA) and were cultured in 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES-) and bicarbonate-buffered Dulbecco’s Modified
Eagle Medium (DMEM), supplemented with 10% heat-
inactivated fetal calf serum and with antibiotics (penicil-
lin, streptomycin and amphotericin), in a 37°C incubator
with 5% CO2 and 100% humidity. When ~80% of the tis-
sue culture plates were covered with cells, the cells were
detached with 0.25% Trypsin/EDTA for sub-culturing or
seeding in 12 well tissue culture plates at ~200,000 cells/
cm2. Confluent monolayers were incubated in absence of
antibiotics with adenoviral vectors encoding SAA
(AdSAA;) or a control vector (Adnull), both at a multipli-
city of infection of ~20. The origin and creation of the
adenoviral vectors, with AdSAA encoding the Saa1/2
fusion gene of the CE/J mouse strain (producing SAA2.2
protein), has been described elsewhere [29]. The cells
were incubated for 48 h to allow for SAA expression. To
study regulation of SAA1/2 and SAA3 expression in
CMT93 cells, confluent monolayers were incubated with
various amounts of E. coli LPS (0111:B4; obtained from
Sigma Aldrich) for 16 h. RNA was isolated and tran-
scribed into cDNA prior to real-time PCR analysis with
the following primer pairs (5’ - 3’): CTG CCT GCC AAA
TAC TGA GAG TC/C CAC TTC CAA GTT CCT GTT
TAT TAC (SAA1/2), GCT GGC CTG CCT AAA AGA
TAC TG/G CAT TTC ACA AGT ATT TAT TCA GC
(SAA3), CCA GGT TGT CTC CTG CGA CTT/CCT
GTT GCT GTA GCC GTA TTC A (GAPDH). Melting
curves were obtained after PCR to assess amplicon
quality.
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Bacterial viability assay
A growth curve of E. coli DH5a in Luria Broth (LB) was
generated by correlating light absorption at 600 nm with
the number of colony forming units observed after plat-
ing bacterial dilutions on LB agar. On the morning of
the experiment, a culture was started and bacteria were
allowed to grow until mid-log phase. A total number of
bacteria corresponding to a 100× excess compared to
intestinal epithelial cells was pelleted, washed three
times in PBS, and added as 10× concentrated suspension
to the epithelial cells in their original, adenovirus-
containing antibiotics-free medium. The epithelial cells
were incubated with bacteria for 2 h, at 37°C. Bacteria
were also added to a set of wells lacking epithelial cells
to determine 100% bacterial viability. After the incuba-
tion, serial dilutions of supernatant were spread on LB-
agar, and colonies were enumerated after overnight
incubation at 37°C.
RT-PCR of human colon samples
RNA from biopsies from inflamed and non-inflamed
(“uninvolved”) areas of the terminal ileum and colon of
Crohn’s Disease patients (n = 10) and of controls with
no Crohn’s Disease (n = 5) were reverse transcribed into
cDNA, which was then analyzed for the expression of
SAA1/2 RNA relative to GAPDH RNA by real-time
PCR using primer pairs GTA-GGC-TCT-CCA-CAT-
GTC-CC/TGG-TTT-TCT-GCT-CCT-TGG-TC and
GAA-GGT-GAA-GGT-CGG-AGT-CAA-C/CAG-AGT-
TAA-AAG-CAG-CCC-TGG-T, respectively. The sam-
ples were obtained with permission of the Institutional
Review Board of the University of Kentucky.
Results
Expression of acute-phase SAA in mouse intestinal
epithelium
Sections of mouse colon were incubated with an RNA
probe recognizing both Saa1 and -2 to determine
whether SAA is expressed in mouse intestinal epithe-
lium. Strong staining was observed at the level of the
epithelium (Figure 1A,B), with most of the signal pre-
sent at the tip of the villi (Figure 1E). Expression of the
SAA3 isoform was weaker, but overlapped with the
expression of SAA1/2 (Figure 1C,D). Immunostaining
confirmed the presence of SAA in the mouse intestine,
though the pattern was more diffuse (Figure 1F), per-
haps consistent with release of SAA into apical and
basolateral sides of the epithelium. To test whether SAA
was indeed apically secreted into the lumen, extracts of
fecal excrements from wildtype and SAA-knockout mice
were analyzed by immunoblotting after SDS-polyacryla-
mide electrophoresis. As shown in Figure 2B, immunor-
eactivity was indeed observed in fecal extracts,
consistent with secretion of SAA into the gut. Thus,
Figure 1 Intestinal SAA expression and secretion. SAA1/2 RNA,
represented by the black signal in A and E, or the white signal in
the counter-stained image B, was readily detectable in cross-
sections of colonic epithelia (A, B), and was mainly located at the
villous tips (E). SAA3 message showed similar distribution, but was
much weaker (black signal in C, white in counter-stained image D).
SAA immunostaining (green signal) showed a more diffuse pattern
than SAA RNA, with SAA protein expressed along the crypt-villus
axis (F), perhaps reflecting secretion of SAA by intestinal epithelial
cells into the apical and basolateral milieu. A,C and E represent
bright-field images, B and D dark-field images.
Figure 2 SAA levels in plasma and stool of knockout and
wildtype mice. Samples of acute phase plasma, obtained 24 h after
intravenous injection of 1 microgram LPS into wildtype mice or
DKO mice (A), or extracts of stool samples from wildtype mice (B)
were analyzed by immunoblotting with anti SAA1/2 antiserum
following SDS-PAGE. The right lane in “B”, labeled “SAA”, is a
positive control consisting of acute-phase plasma obtained as
described for panel A. The reduced mobility of SAA in stool samples
is likely caused by self-aggregation of SAA.
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SAA is expressed in the intestinal epithelium, and is
secreted into the gut lumen.
To confirm intestinal expression of SAA, RNA was
extracted from intestinal segments, and cDNA was ana-
lyzed by PCR with primers recognizing a common frag-
ment of mRNA encoded by Saa1 and 2. As shown in
Figure 3A, strong signal was detected in the colon, with
weaker signals in the ileum. This finding could suggest a
link between bacterial load and SAA expression. To test
this possibility, intestinal tissue was obtained from
germfree mice and analyzed for expression of SAA1/2.
Surprisingly, whereas expression was nearly absent from
the ileum, significant message was still detectable in the
colons of germfree mice, suggesting that colonic expres-
sion is constitutive and may be independent of the pre-
sence of bacterial factors. To further test regulation of
SAA expression in intestinal epithelial cells as a function
of bacterial load, we used CMT93 cells, a mouse rectal
epithelial line. Whereas SAA1/2 expression did not
increase with increasing exposure to LPS and was
already high without added LPS, SAA3 expression
appeared to be strongly inducible (Figure 3B).
Intestinal epithelial SAA expression reduces bacterial
growth
SAA expression has been shown to facilitate the killing of
Gram-negative bacteria by phagocytes [15]. Since SAA is
highly expressed in the intestinal epithelium, we hypothe-
sized that SAA also affects the viability of gram-negative
bacteria cultured in proximity of intestinal epithelial
cells. To test this hypothesis, SAA expression in CMT93
and HT29 cells was stimulated by transduction with
AdSAA whereas controls received AdNull. After 48 h,
the cells were exposed for 2 h to E. coli DH5a (~100 bac-
teria per epithelial cell), and residual bacterial viability
was assessed by plating serial dilutions of the conditioned
media on LB agar. As shown in Figure 4, SAA over-
expression significantly decreased bacterial viability in
the co-culture experiments, for both cell lines.
SAA protects against DSS colitis
Failure to limit bacterial load at the intestinal epithelium
increases the risk for inflammatory bowel disease, and
since SAA might contribute to clearance of E. coli from
the epithelium, we hypothesized that lack of SAA would
increase the susceptibility to experimental colitis. To
test this hypothesis, DKO mice and wildtype littermates
were exposed to 3% DSS in their drinking water for one
Figure 3 SAA expression in mouse colon and ileum and in
response to LPS. RNA was isolated from the colon and ileum of
germfree or conventionally raised mice, and cDNA was amplified
with oligonucleotides recognizing a common region of SAA1/2 (A).
In conventional mice, SAA1/2 was detected in colon and ileum,
whereas in germfree mice, SAA1/2 was only detectable in the
colon. In (B), CMT93 cells were incubated with the indicated
amounts of LPS for 16 h, and SAA1/2 and SAA3 expression were
determined with realtime PCR. Whereas SAA1/2 message remained
rather constant, SAA3 expression markedly increased with increased
LPS exposure. Each group contained data on 4 wells. Shown are
average ± S.E.M. The asterisk indicates statistically significant
differences (P < 0.05) compared with un-induced cells (ANOVA).
Figure 4 SAA over-expression in cultured IEC reduces viability
of co-cultured E. coli. CMT93 or HT29 cells were grown on plastic
supports until confluency, in medium without antibiotics. The cells
were then incubated with ~20 multiplicities of infection of AdNull
or AdSAA, and 48 h later, 100 cfu E. coli were added per cell for 2 h
at 37°C. A small amount of medium was removed to detect SAA
expression by Western blotting (A). After the 2 h incubation, serial
dilutions of the culture media were grown on LB-agar. The Y-axis
shows the fraction (%) of surviving bacteria relative to the positive
controls (bacteria grown in cell-free medium). Show are averages ±
S.D. of triplicate wells per group of a typical experiment that was
conducted three times with similar outcome. The difference
between AdSAA and Adnull treated groups was statistically
significant (t-test; P < 0.05).
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week, and colitis severity was determined. Figure 2A
shows absence of SAA immunoreactivity in plasma of
DKO mice after injection with bacterial LPS, illustrating
that the saa1 and saa2 genes were successfully inacti-
vated. As shown in Figure 5, DKO mice lost more
weight, had increased histological disease scores, lost
more blood as reflected by a decrease in hematocrit,
and showed increased colon shortening compared to
controls. However, only the differences in colon short-
ening and hematocrit values reached statistical signifi-
cance. Pronounced differences were observed in the
expression of TNFalpha and osteopontin in the colons
of DSS-treated mice. DSS-treated DKO mice showed
substantially increased TNFalpha and osteopontin
mRNA levels compared to wildtype controls. Non-DSS
treated mice showed little expression of these pro-
inflammatory cytokines, regardless of genotype.
SAA expression in Crohn’s Disease
In light of the possible involvement of SAA in DSS
colitis, we tested whether intestinal SAA expression is
altered in inflamed and uninflamed tissue from
Crohn’s Disease patients versus non IBD controls.
Inflamed tissue of CD patients showed significantly
increased SAA1/2 expression as compared to controls
and to uninvolved tissue. There was no statistically sig-
nificant difference in gene expression between tissue
from controls and from uninvolved areas of CD
patients (Figure 6).
Discussion
We observed that SAA1/2 and SAA3 are expressed in the
intestinal epithelium, and that SAA protein is secreted
into the gut lumen. Mice lacking functional SAA1/2
expression appeared to be more susceptible to DSS-
induced colitis, which suggests that SAA production and
secretion play a role in intestinal immune homeostasis.
In vitro experiments showed that intestinal-epithelial
SAA expression reduced the viability of co-cultured
E. coli, suggesting that SAA may aid in the local clear-
ance of bacteria. The expression of SAA 1/2 was
increased in intestinal tissue biopsies of Crohn’s Disease
patients, suggesting that SAA is involved in the disease.
One of the major of higher organisms is the interac-
tion with omnipresent bacteria. This is particularly
important at mucosal surfaces, such as the intestinal
epithelium, which can be colonized by large numbers of
bacteria. The seemingly peaceful cohabitation of bacteria
with their host represents a state of “controlled inflam-
mation”, in which the bacteria are prevented from gain-
ing access to the body proper by an array of protective
mechanisms. These include tight-junctions between
epithelial cells [30], a layer of mucus covering the
epithelium [19], secretion of Immunoglobulin-A [20],
Figure 5 SAA protects from experimental colitis. SAA knockout mice (n = 7; white bars) or age and sex-matched controls (n = 7; black bars)
were treated with 3% DSS in their drinking water for 6 days, while control mice (n = 5 per group) received normal water. Colon length (A),
hematocrit (B), bodyweight gain (C), and histological disease index (D) were determined on day 8. Only differences in colon length and
hematocrit values were statistically significant (P < 0.05, ANOVA). Real-time PCR analysis of colon tissue samples revealed significant increases in
expression of TNFa and osteopontin (OPN) in colon tissue samples of DSS-treated DKO mice (E and F respectively; asterisks indicate significant
differences with other groups (ANOVA and post-hoc analysis; P < 0.05)).
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and an array of bactericidic proteins, enzymes, and pep-
tides [19,21-24]. Deficiencies in one or more of these
mechanisms may cause the intestinal microflora to
adopt an unfavorable species composition or increases
the risk of penetration by bacteria of the intestinal
mucosa. Inflammatory bowel disease pathogenesis is
indeed related to mutations in mechanisms allowing
sensing and killing of bacteria [25,26,31].
We confirm previous reports of intestinal-epithelial
expression of acute-phase SAA [17,32,33]. We also
observed significant expression of SAA3 in IEC of healthy
mice, in agreement with recently published data [34]. The
presence of SAA3 in the epithelia is interesting, since this
isoform was thought to be mainly expressed in macro-
phages [35]. Intuitively, since SAA is generally considered
pro-inflammatory [12-14,36], one would predict that lack
of SAA would result in less severe DSS colitis. We have
previously demonstrated that lack of another pro-inflam-
matory factor, osteopontin, protects from DSS-induced
colitis [28]. And yet, the DKO mice appeared to be more
susceptible to DSS-induced colitis. One possible explana-
tion is that SAA could help reduce bacterial growth near
the intestinal epithelium. Recently, it was shown that
plasma SAA interacts with E. coli, presumably by binding
to OmpA (outer membrane protein A) in the cell wall,
thereby facilitating internalization and destruction of the
bacteria by neutrophils and macrophages [15]. We
observed that SAA overexpression in IEC significantly
reduces survival of co-cultured E. coli. We are currently
investigating the mechanism for the bactericidal effect of
SAA. One possibility is that, as with neutrophils, intest-
inal epithelial cells internalize E. coli opsonized by SAA.
IEC are capable of generating bacteriocidic reactive
oxygen species [37], and are also able to internalize
E. coli via phagocytosis [38]. We [39] and others [40-43]
have demonstrated significant expression of a candidate
phagocytic receptor, Scavenger Receptor BI (SR-BI), on
the apical surface of IEC. In non-professional phagocytes,
such as HEK-293 cells, SR-BI strongly promotes phago-
cytosis [44]. As our group has shown, SR-BI also acts as a
receptor for SAA [45], and we are currently investigating
the role of SR-BI/SAA in the phagocytosis of bacteria
and uptake of LPS into IEC. Together, these data suggest
a model in which intestinal epithelial expression of SAA
protects from colitis by reducing bacterial load. We also
observed that intestinal biopsies from Crohn’s Disease
patients showed increased SAA expression. Crohn’s Dis-
ease is related to local defects in bacterial sensing and
killing mechanisms [25,26,31], and we speculate that
SAA is upregulated in Crohn’s Disease in an attempt to
compensate for these defects and to protect the intestinal
tissue. Detailed studies are required to test this
hypothesis.
We have previously shown that DSS-induced colitis
leads to a strong increase in circulating levels of acute-
phase SAA [27,28], which is likely mainly derived from
the liver. DSS-colitis is characterized by destruction of
the intestinal epithelium, and is therefore expected to
result in significant translocation of bacteria into the
portal circulation. The first major organ that would
encounter translocated gut bacteria is the liver. Thus,
SAA would not merely be a marker for inflammation,
but it could be secreted by the liver in large amounts in
order to stem the spreading of translocated Gram-nega-
tive bacteria. Therefore, intestinal epithelial and hepatic
SAA could act as a complementary, two-pronged
mechanism of defense against intestinal Gram-negative
bacteria.
Conclusions
We have demonstrated that SAA, and likely intestinal
epithelial SAA, protects from experimental colitis. At
least in vitro, intestinal epithelial SAA expression greatly
reduces the viability of co-cultured E. coli.
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